Your browser doesn't support javascript.
loading
Simultaneous expression of TTF1 and GATA3 in a lung biopsy sample: confusion in diagnostic pathology.
Zhao, Lianhua; Mao, Chengyi; Xiao, He; Fu, Ping; Xiao, Hualiang; Chen, Chuan; Wang, Ge.
Afiliação
  • Zhao L; Department of Pathology, Daping Hospital, Army Medical University No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China.
  • Mao C; Department of Pathology, Daping Hospital, Army Medical University No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China.
  • Xiao H; Cancer Center, Daping Hospital, Army Medical University No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China.
  • Fu P; Department of Pathology, Daping Hospital, Army Medical University No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China.
  • Xiao H; Department of Pathology, Daping Hospital, Army Medical University No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China.
  • Chen C; Cancer Center, Daping Hospital, Army Medical University No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China.
  • Wang G; Cancer Center, Daping Hospital, Army Medical University No. 10 Changjiang Zhilu, Yuzhong District, Chongqing 400042, China.
Int J Clin Exp Pathol ; 12(9): 3613-3619, 2019.
Article em En | MEDLINE | ID: mdl-31934211
ABSTRACT

BACKGROUND:

In daily work, pathologists often use TTF1 and GATA3 in the differential diagnosis of primary lung adenocarcinoma (TTF1+ GATA3-) and metastatic bladder cancer (or breast cancer) (TTF1- GATA3+). However, we encountered a small lung biopsy sample of TTF1+ GATA3+ (clinically suggesting both lung and bladder occupancy), and the dyeing results caused us great confusion; thus, we intended to determine the expressions of TTF1 and GATA3 in lung and bladder cancer by expanding the sample.

METHODS:

The study included a complete case report and the tissue microarrays including pulmonary squamous cell carcinomas (n = 55), lung adenocarcinomas (n = 47), high-grade (n = 68) and low-grade (n = 43) urothelial carcinomas of the bladder. TTF1 and GATA3 immunohistochemical staining were performed on the tissue microarrays, and the relevant literature was retrieved.

RESULTS:

Our staining results on tissue microarrays showed that TTF1 was expressed in pulmonary adenocarcinomas (44/47, 93.6%), squamous cell carcinomas (1/55, 1.8%), low-grade (1/43, 2.3%) and high-grade (2/68, 2.9%) urothelial carcinomas; GATA3 was only expressed in urothelial carcinomas of the bladder (high-grade 48/68, 70.6%; low-grade 42/43, 97.7%). Our literature search results showed that TTF1 could be expressed in a very small number of bladder urothelial carcinomas, and GATA3 could be expressed in a few primary lung squamous cell carcinomas and a very small number of primary lung adenocarcinomas.

CONCLUSIONS:

TTF1 and GATA3 are good markers in the differential diagnosis of primary non-small cell lung cancer (GATA3-) and metastatic urothelial carcinoma of the bladder (GATA3+). However, pathologists should pay attention to a few special cases lung cancer may express GATA3, and urothelial carcinoma may express TTF1. In these cases, some additional immunohistochemical markers, such as napsin A and URO III, should be added to assist the diagnosis.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article